Last updated: February 14, 2026
What Is the Drug and Its Approved Indication?
NDG: 00245-0809 is identified as Erdafitinib (Balversa). It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of locally advanced or metastatic urothelial carcinoma with specific FGFR gene alterations[1].
Market Overview
Target Patient Population
- Urothelial carcinoma: Approximately 81,400 new cases annually in the U.S. (2023 estimates).
- Patients with FGFR mutations or gene fusions: Roughly 20-30% of urothelial carcinoma patients[2].
- Eligible patients for Erdafitinib: Estimated at 16,000 to 24,000 annually in the U.S.
Competitive Landscape
- Other FGFR inhibitors include:
- Pemigatinib (Pemazyre): Approved for cholangiocarcinoma with FGFR2 fusions.
- Futibatinib (Tibimet): Under review and in trials for FGFR-driven cancers.
- Monotherapy or combination therapies in clinical trials focus on FGFR-altered tumors, expanding potential treatment options.
Market Trends
- Increasing detection of FGFR alterations through Molecular Diagnostics (e.g., NGS-based tests), driving targeted therapy use.
- Growing adoption of personalized cancer therapies.
- The urothelial carcinoma market expected to reach $3.5 billion globally by 2025, with FGFR-targeted treatments capturing rising market share[3].
Pricing Dynamics
Current Pricing for Erdafitinib
- Listed wholesale acquisition cost (WAC): approximately $17,000 to $18,000 per month (per 2023 data).
- Annual treatment cost: around $204,000 to $216,000.
Price Comparisons
| Drug |
Annual Cost |
Indication |
Pricing Notes |
| Erdafitinib |
~$210,000 |
Urothelial carcinoma |
Based on wholesale acquisition cost (WAC) |
| Pemigatinib |
~$180,000 |
Cholangiocarcinoma |
Slightly lower, based on similar dosing |
| Futibatinib (pending approval) |
N/A |
Under clinical trials |
Estimated similar to Erdafitinib |
Payer and Reimbursement Outlook
- High-cost cancer treatments are often reimbursed by Medicare/Medicaid and commercial insurers.
- Cost-sharing agreements can influence patient access.
- Off-label use less common due to specific molecular testing requirement.
Future Price Projections
Factors Influencing Price Trends
- Patent expiration potentially in 2029-2030, leading to generic competition.
- Patent extensions or new indications could maintain exclusivity.
- Competition via clinical trial results or new drugs could pressure prices down.
Forecast (next 5 years)
- Presuming patent protection and market exclusivity:
- Stable pricing at ~$17,000/month.
- Potential decrease post-patent expiry:
- Could fall to ~$10,000/month or less, matching generics' pricing for similar targeted therapies.
- Entry of biosimilars or generic equivalents could further reduce prices by 20-50%.
Strategic Market Entry Considerations
- Clinical differentiation via combination therapies could sustain premium pricing.
- Expansion into other FGFR-driven cancers could justify sustained high prices.
- Negotiated discounts with payers and cost-sharing policies influence real-world pricing.
Key Takeaways
- NDG: 00245-0809 (Erdafitinib) has a niche within FGFR-altered urothelial carcinoma, with an addressable patient pool of approximately 16,000-24,000 annually in the U.S.
- Current annual cost: approximately $210,000, positioned at the higher end for targeted cancer therapies.
- The market is supported by increasing molecular testing, with growth driven by personalized medicine trends.
- Price stability expected for 3-5 years, with potential reductions after patent expiration.
- Competition and drug pipeline developments could influence future pricing and market share.
Frequently Asked Questions
1. When will Erdafitinib face generic competition?
Patent expiration expected around 2029-2030, after which generic versions may significantly reduce prices.
2. What factors could extend Erdafitinib’s market exclusivity?
New indications, clinical trial success in other cancers, or patent extensions based on formulation or delivery method.
3. How do prices compare internationally?
U.S. prices are higher than in Europe and Asia, where pricing is often regulated or negotiated downward.
4. Is targeted molecular testing a barrier?
Yes. Testing for FGFR alterations is necessary, which may limit broad access but simultaneously confirms appropriate patient selection and sustains value.
5. How does the competition impact pricing strategies?
Pending approvals and clinical outcomes of competing FGFR inhibitors can lead to price adjustments and market share shifts.
References
[1] FDA. (2020). FDA approves Erdafitinib for urothelial carcinoma.
[2] Ghosn, M. et al. (2021). FGFR alterations in urothelial carcinoma. Journal of Oncology.
[3] MarketsandMarkets. (2022). Global oncology market forecast.
